PAT Plus Three-Batch Validation Suggested As Transition Approach By FDA
This article was originally published in The Tan Sheet
Executive Summary
Process analytical technologies (PAT) and conventional manufacturing validation methods could be implemented concurrently as a way to avoid product introduction delays during the transition to the new validation approach, FDA suggests
You may also be interested in...
Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record
FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities
Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record
FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities
Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record
FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities